These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 30625070)

  • 1. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
    Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
    N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
    N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
    Hollifield AL; Arnall JR; Moore DC
    Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience with caplacizumab in the management of acute TTP.
    Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
    Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
    Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y
    Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.
    Knoebl P; Cataland S; Peyvandi F; Coppo P; Scully M; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
    J Thromb Haemost; 2020 Feb; 18(2):479-484. PubMed ID: 31691462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
    le Besnerais M; Veyradier A; Benhamou Y; Coppo P
    Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
    [No Abstract]   [Full Text] [Related]  

  • 9. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
    Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
    Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
    Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
    Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
    Poullin P; Bornet C; Veyradier A; Coppo P
    Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.
    Peyvandi F; Cataland S; Scully M; Coppo P; Knoebl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
    Blood Adv; 2021 Apr; 5(8):2137-2141. PubMed ID: 33881463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
    Elverdi T; Eskazan AE
    Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining the standard of care in immune thrombotic thrombocytopenic purpura.
    Laurence J
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):381-391. PubMed ID: 39356816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience.
    Taylor A; Keogh L; Dickens E; Dutt T; Grainger J; Gregory R; Mapplebeck C; Richards M; Stokley S; Salta S; Taylor T; Scully M
    Blood Adv; 2024 Sep; 8(17):4563-4567. PubMed ID: 38968147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.
    Dane K; Chaturvedi S
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):539-547. PubMed ID: 30504355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
    Tsai HM
    Am J Med; 2019 Sep; 132(9):1032-1037. PubMed ID: 30928346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.
    Mingot-Castellano ME; García-Candel F; Martínez-Nieto J; García-Arroba J; de la Rubia-Comos J; Gómez-Seguí I; Paciello-Coronel ML; Valcárcel-Ferreiras D; Jiménez M; Cid J; Lozano M; García-Gala JM; Angós-Vazquez S; Vara-Pampliega M; Guerra-Domínguez L; Ávila-Idrobo LF; Oliva-Hernandez A; Zalba-Marcos S; Tallón-Ruiz I; Ortega-Sánchez S; Goterris-Viciedo R; Moreno-Jiménez G; Domínguez-Acosta L; Araiz-Ramírez M; Hernández-Mateos L; Flores-Ballesteros E; Del Río-Garma J; Pascual-Izquierdo C
    Blood; 2024 May; 143(18):1807-1815. PubMed ID: 38237147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.
    Miyakawa Y; Imada K; Ichikawa S; Uchiyama H; Ueda Y; Yonezawa A; Fujitani S; Ogawa Y; Matsushita T; Asakura H; Nishio K; Suzuki K; Hashimoto Y; Murakami H; Tahara S; Tanaka T; Matsumoto M
    Int J Hematol; 2023 Mar; 117(3):366-377. PubMed ID: 36427162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).
    Estcourt LJ
    Transfus Med; 2019 Jun; 29(3):146-148. PubMed ID: 31318128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.